Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 11/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10281191 | 0.79 | PTGS1 (0.46) | PTGS1PTGS2HTTALDH1A1 | |
| SCHEMBL1024205 | 0.76 | PTGS1 (0.54) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL9941076 | 0.76 | KIF11 (0.37) | PTGS1PTGS2ALDH1A1 | |
| SCHEMBL8266257 | 0.72 | PTGS1 (0.67) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL1022376 | 0.72 | PTGS1 (0.50) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL1019980 | 0.69 | PTGS1 (0.48) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL1022946 | 0.69 | PTGS1 (0.44) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL1021358 | 0.68 | PTGS1 (0.43) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL7627881 | 0.68 | PTGS2 (0.61) | PTGS1PTGS2HTTALDH1A1 | |
| SCHEMBL1020604 | 0.68 | PTGS1 (0.47) | PTGS1PTGS2HTTUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937264-B1 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK SHARP & DOHME (US) | 2011-06-08 | — | — | EP | disclosed |
| US-7893091-B2 | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence | MERCK SHARP & DOHME CORP. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| EP-1937264-A2 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | Merck & Co., Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007146224-A2 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007044296-A2 | COMBINATION THERAPY FOR THE TREATMENT OF URINARY FREQUENCY, URINARY URGENCY AND URINARY INCONTINENCE | MERCK & CO., INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196113-B2 | Lactam tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1761488-A1 | LACTAM TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006002117-A1 | LACTAM TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050282886-A1 | Lactam tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2005-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270406-A1 | Combination Therapy for the Treatment of Urinary Frequency, Urinary Urgency and Urinary Incontinence | MME, UTS2R, BPHL | PTGS1 1013/4885PTGS2 991/4885HTT 2456/4885 |
| US-20050282886-A1 | Lactam tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | PTGS1 294/4885PTGS2 1257/4885HTT 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.